Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 31

Sort by

Sort Order Select

Journal Articles

Understanding the Lived Experience of Fatigue in Adolescents and Young Adults with Myeloproliferative Neoplasms: A Mixed Methods Study

Steve Dagenais-Bellefeuille, Karine Bilodeau, Alisa Poullet, Shireen Sirhan, Robert Delage, Ghislain Cournoyer, Ines Chamakhi, Danielle Talbot, Luigina Mollica, Daniele Marceau, Vincent Ethier, Pierre Desjardins, Harold J. Olney, Michaël Harnois, Lambert Busque, Natasha Szuber

Blood (2024) 144 (Supplement 1): 408.

https://doi.org/10.1182/blood-2024-206225

Published: 2024

Journal Articles

Addressing Unmet Needs in the Management of Drug-Induced Secondary Erythrocytosis: Results from an International Physician Survey

Natasha Szuber, Lambert Busque, Harold J. Olney, Luigina Mollica, Shireen Sirhan

Blood (2024) 144 (Supplement 1): 7697.

https://doi.org/10.1182/blood-2024-207623

Published: 2024

Journal Articles

Allogeneic Hematopoietic Stem Cell Transplant for B-Cell Lymphomas in the Era of Novel Cellular Therapies: Experience from a Tertiary Canadian Center

Mathias Castonguay, Jean-Sébastien Claveau, Jean Roy, Sandra Cohen, Sylvie Lachance, Imran Ahmad, Nadia M. Bambace, Lea Bernard, Jean-Sebastien Delisle, Thomas L. Kiss, Isabelle Fleury, Luigina Mollica, Denis-Claude Roy, Guy Sauvageau, Olivier Veilleux

Blood (2024) 144 (Supplement 1): 7446.

https://doi.org/10.1182/blood-2024-210718

Published: 2024

Journal Articles

Prognosis of Progressive Follicular Lymphoma within 24 Months of First-Line Therapy Is Not Influenced By the Initial Regimen Intensity

Camille Gauvin, Imran Ahmad, Luigina Mollica, Sandra Cohen, Olivier Veilleux, Sylvie Lachance, Isabelle Fleury

Blood (2023) 142 (Supplement 1): 6150.

https://doi.org/10.1182/blood-2023-183021

Published: 2023

Journal Articles

Prospective Symptom Burden Analysis in 784 Patients with Myeloproliferative Neoplasms: High Burden Correlates with Inflammatory/Genetic Biomarkers and Reduced Survival

Alisa Poullet, Lambert Busque, Shireen Sirhan, Robert Delage, Ghislain Cournoyer, Ines Chamakhi, Danielle Talbot, Luigina Mollica, Daniele Marceau, Vincent Ethier, Pierre Desjardins, Harold J. Olney, Michaël Harnois, Natasha Szuber

Blood (2023) 142 (Supplement 1): 917.

https://doi.org/10.1182/blood-2023-183005

Published: 2023

Journal Articles

Geographical CAR-T Unmet Needs for Patients with Large B-Cell Lymphoma in the Province of Quebec

Maria Murphy, Mathilde Fromentin, Julie Campeau, Michael Sebag, Félix Couture, Jean-François Larouche, Christopher Lemieux, Silvy Lachance, Sandra Cohen, Luigina Mollica, Olivier Veilleux, Isabelle Fleury

Blood (2022) 140 (Supplement 1): 13228–13229.

https://doi.org/10.1182/blood-2022-156473

Published: 2022

Journal Articles

Very Elderly Patients with Myeloproliferative Neoplasms: Phenotypic Distinctions and Prognostic Determinants of Complications and Mortality

Judith Jolin, Michael Harnois, Luigina Mollica, Pierre Laneuville, Robert Delage, Harold J. Olney, Shireen Sirhan, Lambert Busque, Natasha Szuber

Blood (2021) 138 (Supplement 1): 2572.

https://doi.org/10.1182/blood-2021-145131

Published: 2021

Journal Articles

Quantitative Trait of Neutrophil Count Is Influenced By Variants in the Region of Gsdma and PSMD3-CSF3, a ging, Cardiometabolic Comorbidities but Not By Chip

Marie-France Gagnon, Sylvie Provost, Sami Ayachi, Manuel Buscarlet, Luigina Mollica, Marie-Pierre Dubé, Lambert Busque

Blood (2021) 138 (Supplement 1): 1089.

https://doi.org/10.1182/blood-2021-151555

Published: 2021

Journal Articles

Secondary Erythrocytosis Is Phenotypically Distinct from Polycythemia Vera but Associated with Comparable Rates of Thrombosis at Diagnosis

Eliane Nguyen, MD, Natasha Szuber, MD, Michael Harnois, Lambert Busque, MD, Luigina Mollica, MD FRCPC, PhD, Sarit E Assouline, MD MSc, Ines Chamakhi, MD MD FRCP(C), Harold J. Olney, MD, Shireen Sirhan, MD

Blood (2020) 136 (Supplement 1): 4–7.

https://doi.org/10.1182/blood-2020-141835

Published: 2020

Journal Articles

Copanlisib, a PI3K Inhibitor, Demonstrates a Favorable Long-Term Safety Profile in a Pooled Analysis of Patients with Hematologic Malignancies

Pier Luigi Zinzani, MD, Armando Santoro, Luigina Mollica, MD FRCPC, PhD, Sirpa Leppä, MD PhD, George A Follows, MD PhD, Georg Lenz, MD, Won Seog Kim, MD PhD, Arnon Nagler, MD MSc, Panayiotis Panayiotidis, MD, Judit Demeter, MD PhD Dr. Sci, Franck Morschhauser, MD, Javier Munoz, MD MS, FACP, Ashok Miriyala, MD, Alice Benson, PhD, Jose Garcia-Vargas, MD, Barrett H Childs, MD, Martin Dreyling, MD

Blood (2019) 134 (Supplement_1): 4009.

https://doi.org/10.1182/blood-2019-131779

Published: 2019

Journal Articles

Long-Term Efficacy and Safety of Copanlisib in Multiply Relapsed or Refractory Patients with Marginal Zone Lymphoma

Martin Dreyling, MD, Panayiotis Panayiotidis, MD, George A Follows, MD PhD, Luigina Mollica, MD FRCPC, PhD, Arnon Nagler, MD MSc, Muhit Özcan, MD, Armando Santoro, Don Stevens, MD, David Trevarthen, MD, Florian Hiemeyer, MSc, Li Liu, PhD, Jose Garcia-Vargas, MD, Barrett H Childs, MD, Pier Luigi Zinzani, MD PhD

Blood (2019) 134 (Supplement_1): 1531.

https://doi.org/10.1182/blood-2019-121932

Published: 2019

Journal Articles

Long-Term Efficacy and Safety from the Copanlisib CHRONOS-1 Study in Patients with Relapsed or Refractory Indolent B-Cell Lymphoma

Blood (2018) 132 (Supplement 1): 1595.

https://doi.org/10.1182/blood-2018-99-114842

Published: 2018

Journal Articles

Outcomes for Patients with Pre-Existing Diabetes or Hypertension Treated with Copanlisib from the CHRONOS-1 Study in Patients with Relapsed or Refractory Indolent B-Cell Lymphoma

Pier Luigi Zinzani, MD, Armando Santoro, MD, Luigina Mollica, MD FRCPC, PhD, Sirpa Leppä, MD PhD, George A Follows, MD PhD, Georg Lenz, Won Seog Kim, MD PhD, Arnon Nagler, MD, Panayiotis Panayiotidis, MD PhD, Judit Demeter, MD PhD Dr. Sci, Franck Morschhauser, MD, Liana Rodrigues, MD, John Reeves, PhD MS, Florian Hiemeyer, MSc, Ashok Miriyala, MD, Jose Garcia-Vargas, MD, Barrett H. Childs, MD, Martin H. Dreyling, MD PhD

Blood (2018) 132 (Supplement 1): 1613.

https://doi.org/10.1182/blood-2018-99-117063

Published: 2018

Journal Articles

Outcomes for Patients with High-Risk Relapsed or Refractory Indolent B-Cell Lymphoma Treated with Copanlisib in the CHRONOS-1 Study

Armando Santoro, MD, Luigina Mollica, MD PhD, Sirpa Leppa, MD Prof, George A Follows, MD PhD, Georg Lenz, Won Seog Kim, MD PhD, Arnon Nagler, MD, Maria Dimou, MD PhD, Judit Demeter, MD PhD Dr. Sci, Massimo Magagnoli, MD, Liana Rodrigues, MD, Oliver Wirtz, MSc, Florian Hiemeyer, MSc, Li Liu, PhD, Karl Koechert, PhD, Jose Garcia-Vargas, MD, Barrett H Childs, MD, Pier Luigi Zinzani, MD, Martin H. Dreyling, MD PhD

Blood (2018) 132 (Supplement 1): 395.

https://doi.org/10.1182/blood-2018-99-116715

Published: 2018

Journal Articles

Lineage restriction analyses in CHIP indicate myeloid bias for TET2 and multipotent stem cell origin for DNMT3A

Manuel Buscarlet, Sylvie Provost, Yassamin Feroz Zada, Vincent Bourgoin, Luigina Mollica, Marie-Pierre Dubé, Lambert Busque

Blood (2018) 132 (3): 277–280.

https://doi.org/10.1182/blood-2018-01-829937

Published: 2018

Journal Articles

Efficacy of Copanlisib Monotherapy in Patients with Relapsed or Refractory Marginal Zone Lymphoma: Subset Analysis from the CHRONOS-1 Trial

Martin Dreyling, MD PhD, Panayiotis Panayiotidis, MD PhD, Miklos Egyed, MD PhD, George Follows, MA, PhD FRCP, FRCPath, BM, BCh, Luigina Mollica, MD PhD, Arnon Nagler, MD, Muhit Ozcan, MD, Armando Santoro, MD, Tatiane Ishida, MD, Cindy Lu, PhD, Florian Hiemeyer, MSc, Jose Garcia-Vargas, MD, Barrett H. Childs, MD, Pier Luigi Zinzani, MD PhD

Blood (2017) 130 (Supplement 1): 4053.

https://doi.org/10.1182/blood.V130.Suppl_1.4053.4053

Published: 2017

Journal Articles

Pooled Safety Analysis from Phase I and II Studies for Patients with Relapsed Indolent Non-Hodgkin's Lymphoma Treated with Intravenous Copanlisib

Pier Luigi Zinzani, MD PhD, Amita Patnaik, MD FRCP, Franck Morschhauser, MD PhD, Gilles Andre Salles, MD PhD, Armando Santoro, MD, Luigina Mollica, MD PhD, Krimo Bouabdallah, MD, David Cunningham, MD FRCP, Sirpa Leppa, MD, George Follows, MA, PhD FRCP, FRCPath, BM, BCh, Alice Benson, PhD, Peter Bonata, PhD, Isabelle Genvresse, MD, Ashok Miriyala, MD, Aruna Mehra, MD, Jose Garcia-Vargas, MD, Barrett H. Childs, MD, Martin Dreyling, MD PhD

Blood (2017) 130 (Supplement 1): 4042.

https://doi.org/10.1182/blood.V130.Suppl_1.4042.4042

Published: 2017

Journal Articles

Updated Safety and Efficacy from the Copanlisib CHRONOS-1 Trial in Patients with Relapsed or Refractory Indolent B-Cell Lymphoma: Low Incidence of Late-Onset Severe Toxicities

Blood (2017) 130 (Supplement 1): 2777.

https://doi.org/10.1182/blood.V130.Suppl_1.2777.2777

Published: 2017

Journal Articles

DNMT3A and TET2 dominate clonal hematopoiesis and demonstrate benign phenotypes and different genetic predispositions

Manuel Buscarlet, Sylvie Provost, Yassamin Feroz Zada, Amina Barhdadi, Vincent Bourgoin, Guylaine Lépine, Luigina Mollica, Natasha Szuber, Marie-Pierre Dubé, Lambert Busque

Blood (2017) 130 (6): 753–762.

https://doi.org/10.1182/blood-2017-04-777029

Published: 2017

Includes: Supplemental data

Journal Articles

Timely Molecular Monitoring and Achievement of Major Molecular Response in Chronic Myeloid Leukemia

Adi J. Klil-Drori, MD, Laurent Azoulay, PhD, Hui Yin, MSc, Alexa Del Corpo, Michaël Harnois, MSc, Michel-Olivier Gratton, MSc, Ines Chamakhi, MD, Robert Delage, MD MSc, FRCP, Luigina Mollica, MD PhD, Pierre Laneuville, MD FRCPC, Harold J. Olney, MD CM, Lambert Busque, MD, Sarit E. Assouline, MDMSc

Blood (2016) 128 (22): 3072.

https://doi.org/10.1182/blood.V128.22.3072.3072

Published: 2016

NARROW

Understanding the Lived Experience of Fatigue in Adolescents and Young Adults with Myeloproliferative Neoplasms: A Mixed Methods Study

Addressing Unmet Needs in the Management of Drug-Induced Secondary Erythrocytosis: Results from an International Physician Survey

Allogeneic Hematopoietic Stem Cell Transplant for B-Cell Lymphomas in the Era of Novel Cellular Therapies: Experience from a Tertiary Canadian Center

Prognosis of Progressive Follicular Lymphoma within 24 Months of First-Line Therapy Is Not Influenced By the Initial Regimen Intensity

Prospective Symptom Burden Analysis in 784 Patients with Myeloproliferative Neoplasms: High Burden Correlates with Inflammatory/Genetic Biomarkers and Reduced Survival

Geographical CAR-T Unmet Needs for Patients with Large B-Cell Lymphoma in the Province of Quebec

Very Elderly Patients with Myeloproliferative Neoplasms: Phenotypic Distinctions and Prognostic Determinants of Complications and Mortality

Quantitative Trait of Neutrophil Count Is Influenced By Variants in the Region of Gsdma and PSMD3-CSF3, a ging, Cardiometabolic Comorbidities but Not By Chip

Secondary Erythrocytosis Is Phenotypically Distinct from Polycythemia Vera but Associated with Comparable Rates of Thrombosis at Diagnosis

Copanlisib, a PI3K Inhibitor, Demonstrates a Favorable Long-Term Safety Profile in a Pooled Analysis of Patients with Hematologic Malignancies

Long-Term Efficacy and Safety of Copanlisib in Multiply Relapsed or Refractory Patients with Marginal Zone Lymphoma

Long-Term Efficacy and Safety from the Copanlisib CHRONOS-1 Study in Patients with Relapsed or Refractory Indolent B-Cell Lymphoma

Outcomes for Patients with Pre-Existing Diabetes or Hypertension Treated with Copanlisib from the CHRONOS-1 Study in Patients with Relapsed or Refractory Indolent B-Cell Lymphoma

Outcomes for Patients with High-Risk Relapsed or Refractory Indolent B-Cell Lymphoma Treated with Copanlisib in the CHRONOS-1 Study

Lineage restriction analyses in CHIP indicate myeloid bias for TET2 and multipotent stem cell origin for DNMT3A

Efficacy of Copanlisib Monotherapy in Patients with Relapsed or Refractory Marginal Zone Lymphoma: Subset Analysis from the CHRONOS-1 Trial

Pooled Safety Analysis from Phase I and II Studies for Patients with Relapsed Indolent Non-Hodgkin's Lymphoma Treated with Intravenous Copanlisib

Updated Safety and Efficacy from the Copanlisib CHRONOS-1 Trial in Patients with Relapsed or Refractory Indolent B-Cell Lymphoma: Low Incidence of Late-Onset Severe Toxicities

DNMT3A and TET2 dominate clonal hematopoiesis and demonstrate benign phenotypes and different genetic predispositions

Timely Molecular Monitoring and Achievement of Major Molecular Response in Chronic Myeloid Leukemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only